Sitemap - 2021 - Boutique Biotech
Medicenna in the spotlight (part IV)
Affimed in the spotlight (part VII)
Affimed in the spotlight (part VI)
Eloxx Pharmaceuticals in the spotlight (part V)
Medicenna in the spotlight (part III)
Eloxx Pharmaceuticals in the spotlight (part IV)
Affimed in the spotlight (part V)
Affimed in the spotlight (part IV)
Medicenna in the spotlight (part II)
F-Star Therapeutics in the spotlight (part II)
Autolus Therapeutics and F-Star Therapeutics in the spotlight
Fate Therapeutics in the spotlight
Novavax in the spotlight (part VII)
Assessing the Trillium takeout
Eloxx Pharmaceuticals in the spotlight (part III)
ESSA Pharma in the spotlight (part II)
Jounce Therapeutics in the spotlight (part III)
Novavax in the spotlight (part VI)
Novavax in the spotlight (part V)
Magenta Therapeutics in the spotlight (part III)
Eloxx Pharmaceuticals in the spotlight (part II)
Jounce Therapeutics in the spotlight (part II)
Recursion Pharmaceuticals in the spotlight
Eloxx Pharmaceuticals in the spotlight
Verve Therapeutics in the spotlight
Jounce Therapeutics in the spotlight
Novavax in the spotlight (part IV --brief update)
Novavax in the spotlight (part III)
$MGTA update from 2021 ASCO Annual Meeting
Affimed (AFMD) analysis deep-dive
Novo Nordisk stock price action update